Table 2.
Regulation of cAMP pathway proteins in the LC by 5 d of intra-LC infusion of antisense oligonucleotide to CREB: effects in drug-naive rats
| Antisense | Sense | Missense | AS-reversal | |
|---|---|---|---|---|
| Adenylyl cyclase | ||||
| Type VIII | 73 ± 7 (6)* | 104 ± 7 (6) | 106 ± 11 (5) | |
| Type I | 79 ± 7 (6)2-160 | |||
| Type III | 95 ± 8 (6) | |||
| Protein kinase A | ||||
| Catalytic subunit | 87 ± 3 (11)2-160 | 100 ± 6 (8) | 107 ± 11 (6) | 103 ± 15 (6) |
| Regulatory subunit type II | 85 ± 3 (6)2-160 | 95 ± 14 (6) | ||
| Giα | 94 ± 14 (6) | 97 ± 12 (8) | 103 ± 8 (6) | 113 ± 12 (6) |
| Tyrosine hydroxylase | 82 ± 3 (6)* | 102 ± 11 (6) | 107 ± 12 (7) | 108 ± 14 (6) |
Data are expressed as mean ± SEM percent of contralateral uninfused side (n). Antisense, sense, and missense refer to intra-LC infusion of antisense, sense, or missense oligonucleotide, respectively. AS-reversal refers to intra-LC infusion of antisense oligonucleotide for 5 d followed by 5 d of vehicle infusion.
p < 0.05;
F2-160: p ≈ 0.1 byt test.